110 related articles for article (PubMed ID: 24199803)
61. 7th Advances Against Aspergillosis: Basic, diagnostic, clinical and therapeutic studies.
Cramer RA; Sheppard DC; Clemons KV
Med Mycol; 2017 Jan; 55(1):1-3. PubMed ID: 27994098
[No Abstract] [Full Text] [Related]
62. Could the Lung Be a Gateway for Amphotericin B to Attack the Army of Fungi?
de Carvalho Patricio BF; da Silva Lopes Pereira JO; Sarcinelli MA; de Moraes BPT; Rocha HVA; Gonçalves-de-Albuquerque CF
Pharmaceutics; 2022 Dec; 14(12):. PubMed ID: 36559201
[TBL] [Abstract][Full Text] [Related]
63. The Toxic Mechanism of Gliotoxins and Biosynthetic Strategies for Toxicity Prevention.
Ye W; Liu T; Zhang W; Zhang W
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948306
[TBL] [Abstract][Full Text] [Related]
64. Chronic Pulmonary Aspergillosis: Disease Severity Using Image Analysis and Correlation with Systemic Proinflammation and Predictors of Clinical Outcome.
Huang SF; Huang CC; Chou KT; Chan YJ; Yang YY; Wang FD
J Fungi (Basel); 2021 Oct; 7(10):. PubMed ID: 34682263
[TBL] [Abstract][Full Text] [Related]
65.
Deshmukh H; Speth C; Sheppard DC; Neurauter M; Würzner R; Lass-Flörl C; Rambach G
Front Immunol; 2020; 11():550827. PubMed ID: 33123129
[TBL] [Abstract][Full Text] [Related]
66. Aspergillus fumigatus and Aspergillosis in 2019.
Latgé JP; Chamilos G
Clin Microbiol Rev; 2019 Dec; 33(1):. PubMed ID: 31722890
[No Abstract] [Full Text] [Related]
67. A murine model of cutaneous aspergillosis for evaluation of biomaterials-based local delivery therapies.
Tatara AM; Watson E; Albert ND; Kontoyiannis PD; Kontoyiannis DP; Mikos AG
J Biomed Mater Res A; 2019 Sep; 107(9):1867-1874. PubMed ID: 30882993
[TBL] [Abstract][Full Text] [Related]
68. The Absence of NOD1 Enhances Killing of
Gresnigt MS; Jaeger M; Subbarao Malireddi RK; Rasid O; Jouvion G; Fitting C; Melchers WJG; Kanneganti TD; Carvalho A; Ibrahim-Granet O; van de Veerdonk FL
Front Immunol; 2017; 8():1777. PubMed ID: 29326692
[TBL] [Abstract][Full Text] [Related]
69. Modulation of Host Angiogenesis as a Microbial Survival Strategy and Therapeutic Target.
Osherov N; Ben-Ami R
PLoS Pathog; 2016 Apr; 12(4):e1005479. PubMed ID: 27078259
[No Abstract] [Full Text] [Related]
70. Calcineurin orchestrates dimorphic transitions, antifungal drug responses and host-pathogen interactions of the pathogenic mucoralean fungus Mucor circinelloides.
Lee SC; Li A; Calo S; Inoue M; Tonthat NK; Bain JM; Louw J; Shinohara ML; Erwig LP; Schumacher MA; Ko DC; Heitman J
Mol Microbiol; 2015 Sep; 97(5):844-65. PubMed ID: 26010100
[TBL] [Abstract][Full Text] [Related]
71. Erythropoietin Combined with Liposomal Amphotericin B Improves Outcome during Disseminated Aspergillosis in Mice.
Rousseau N; Picot S; Bienvenu AL
Front Immunol; 2014; 5():502. PubMed ID: 25352847
[TBL] [Abstract][Full Text] [Related]
72. What's new in invasive pulmonary aspergillosis in the critically ill.
Koulenti D; Vogelaers D; Blot S
Intensive Care Med; 2014 May; 40(5):723-6. PubMed ID: 24647810
[No Abstract] [Full Text] [Related]
73. Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis?
Snelders E; Melchers WJ; Verweij PE
Future Microbiol; 2011 Mar; 6(3):335-47. PubMed ID: 21449843
[TBL] [Abstract][Full Text] [Related]
74. Implications of hypoxic microenvironments during invasive aspergillosis.
Wezensky SJ; Cramer RA
Med Mycol; 2011 Apr; 49 Suppl 1(Suppl 1):S120-4. PubMed ID: 20560863
[TBL] [Abstract][Full Text] [Related]
75. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B.
Paterson PJ; Seaton S; Prentice HG; Kibbler CC
J Antimicrob Chemother; 2003 Nov; 52(5):873-6. PubMed ID: 14519673
[TBL] [Abstract][Full Text] [Related]
76. The contribution of Aspergillus fumigatus stress responses to virulence and antifungal resistance.
Brown NA; Goldman GH
J Microbiol; 2016 Mar; 54(3):243-53. PubMed ID: 26920884
[TBL] [Abstract][Full Text] [Related]
77. Angiogenesis at the mold-host interface: a potential key to understanding and treating invasive aspergillosis.
Ben-Ami R
Future Microbiol; 2013 Nov; 8(11):1453-62. PubMed ID: 24199803
[TBL] [Abstract][Full Text] [Related]
78. Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis.
Ben-Ami R; Albert ND; Lewis RE; Kontoyiannis DP
J Infect Dis; 2013 Apr; 207(7):1066-74. PubMed ID: 23303813
[TBL] [Abstract][Full Text] [Related]
79.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
